4L2 Lymphoma, B cell & sentinel (Case 4) neoplastic area CD20 20X | Sentinel & Steroid Rx Lesions | MYELIN (IMMUNE-MEDIATED) | Washington University Experience

Table of Contents

Washington University Experience | MYELIN (IMMUNE-MEDIATED) | Sentinel & Steroid Rx Lesions | 4L2 Lymphoma, B cell & sentinel (Case 4) neoplastic area CD20 20X

Malignant neoplastic B cells are highlighted by CD20 immunoreactivity (CD20 IHC)

| Archive View | Login | Powered by Zenphoto